NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) — Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. If you are a Cellular Biomedicine shareholder, click here to learn more about your rights and options.
Alaska Communications Systems Group, Inc. (NASDAQ: ALSK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ATN International, Inc. for $3.40 per share in cash. If you are an Alaska Communications shareholder, click here to learn more about your rights and options.
Urovant Sciences Ltd. (NASDAQ: UROV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sumitovant Biopharma Ltd. for $16.25 per share. If you are an Urovant shareholder, click here to learn more about your rights and options.
Navistar International Corporation (NYSE: NAV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Traton SE for $44.50 per share in cash. If you are a Navistar shareholder, click here to learn more about your rights and options.
Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related DepressionMUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) --…
- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply…
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered…
"Solo practitioners face unique challenges in managing their credentialing needs," says Olga Khabinskay, Director of…
In Q1 2025, the Company will discuss the plans for NDA submission under a potential…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical…